Assessment of serum levels of DIO1 and DIO3 in patients diagnosed with COPD

[helvella]

It feels as if I am standing in a river in full spate - floodwaters of papers associating thyroid issues with all sorts of other issues. Many of these other issues having no, or only limited, previous association to thyroid.

Of course, we need to ask how serum DIO1 and DIO3 correlate to these enzymes within cells. And numerous other questions.

Adv Med Sci. 2019 Apr 22;64(2):344-348. doi: 10.1016/j.advms.2019.04.001. [Epub ahead of print]

Assessment of serum levels of DIO1 and DIO3 in patients diagnosed with COPD.

Gałecka E1, Kumor-Kisielewska A2, Górski P2.

Author information

1 Department of Pneumology and Allergy, Medical University of Lodz, Lodz, Poland. Electronic address: [e-mail].

2 Department of Pneumology and Allergy, Medical University of Lodz, Lodz, Poland.

Abstract

PURPOSE:

Chronic obstructive pulmonary disease is the most common chronic lung disease, which may be caused by different pathological processes, including inflammation. Furthermore, signs of changes in thyroid hormone levels are found in some patients. Deiodinases (DIOs) are selenoproteins (enzymes) involved in the synthesis of thyroid hormones. It has been found that these molecules are involved in inflammatory processes. We carried out this preliminary study to investigate the levels of two deiodinases, i.e. type 1 deiodinase (DIO1) and type 3 deiodinase (DIO3), and their possible association with COPD and specific clinical parameters.

PATIENTS AND METHODS:

Serum levels of DIO1 and DIO3 as well as lung function parameters were measured in 50 patients suffering from COPD and 30 healthy control subjects. The Mann-Whitney U test and Pearson's correlation coefficient were used to compare and correlate data.

RESULTS:

Serum levels of DIO1 and DIO3 were significantly elevated in COPD patients (97.9 ± 55.6 versus 28.2 ± 28.3 U/L for DIO1 and 19.6 ± 10.7 versus 6.4 ± 6.3 U/L for DIO3; p < 0.001). No correlation between serum levels of the examined DIOs and other sociodemographic and clinical parameters was identified in this study.

CONCLUSION:

For the first time we observed that peripheral DIO1 and DIO3 concentrations were elevated in COPD; hence, we may cautiously begin considering these molecules as potential circulating biomarkers of COPD. It may also be beneficial to conduct further studies to confirm and clarify their potential role.

Copyright © 2019 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.

KEYWORDS:

COPD; Inflammation; Thyroid hormones; Type 1, 3 deiodinases

PMID: 31022560

DOI: 10.1016/j.advms.2019.04.001

ncbi.nlm.nih.gov/pubmed/310...

Abstract only available at journal site - unless you have access:

sciencedirect.com/science/a...

[jimh111]

I saw another study that found higher DIO2 levels in COPD google.com/url?sa=t&rct=j&q... . I've not bothered to read it. The whole point of deiodinase, at least D2 and D3 is that they regulate tissue levels. I can't see how serum levels tell us anything.

The Conclusion states 'we observed that peripheral DIO1 and DIO3 concentrations were elevated in COPD'. They didn't, they observed serum levels. Given the strong associations found it may be useful for confirming diagnosis of COPD but I doubt there's a causative link with thyroid disorders.

[helvella Administrator Thyroid UK in reply to jimh111]

Same authors.